Not Yet RecruitingPhase 1

A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors

China350 participantsStarted 2024-10-31

Plain-language summary

This is a Phase Ib study that will evaluate the Safety, Tolerability , Pharmacokinetics and Activity of HS-10370 in Combination With Other Anti-cancer Therapies in patients with KRAS G12C mutation advanced or metastatic solid tumors, especially in non-Small cell lung cancer (NSCLC) .

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Previous or current treatment with other KRAS G12C inhibitors
✕. Any cytotoxic chemotherapy, anticancer Chinese medicine and targeted small molecule inhibitors within 14 days of the first dose of study treatment; Any investigational agents and large molecule antibodies within 28 days of the first dose of study treatment.
✕. Local radiotherapy within 2 weeks prior to the first dose of study drug, more than 30% of bone marrow irradiation or large-area radiotherapy within 4 weeks before the first dose of study drug.
✕. Major surgery (including craniotomy, thoracotomy, or laparotomy, etc.) within 4 weeks of the first dose

What they're measuring

Number of Participants with Adverse Event(s) (AEs)

Timeframe: From Cycle 1 Day 1 to first documented progression of disease or death from any cause, approximately 2 years.

Trial details

NCT IDNCT06594874

SponsorJiangsu Hansoh Pharmaceutical Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-10-31

Contact for this trial

Xiaorong Dong, PhD

13986252286 xhzzdxr@126.com

View on ClinicalTrials.gov More Non-Small Cell Lung Cancer trials